HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice.

Abstract
The NAD+-dependent deacetylase SIRT1, which is associated with the improvement of metabolic syndromes, such as type 2 diabetes, is a well-known longevity-related gene. Several in vitro and in vivo studies have shown the known protective effects of SIRT1 activators, such as resveratrol and SRT1720, on diabetes- or obesity-induced fatty liver and insulin resistance. Here, we newly synthesized 18 benzoxazole hydrochloride derivatives based on the structure of resveratrol and SRT1720. We performed an in vitro SIRT1 activity assay to identify the strongest SIRT1 activator. The assay confirmed MHY2233 to be the strongest SIRT1 activator (1.5-fold more potent than resveratrol), and docking simulation showed that the binding affinity of MHY2233 was higher than that of resveratrol and SRT1720. To investigate its beneficial effects, db/db mice were orally administered MHY2233 for 1 month, and various metabolic parameters were assessed in the serum and liver tissues. MHY2233 markedly ameliorated insulin signaling without affecting body weight in db/db mice. In particular, the mRNA expression of lipogenic genes, such as acetyl CoA carboxylase, fatty acid synthase, and sterol regulatory element-binding protein, which increased in db/db mice, decreased following oral treatment with MHY2233. In conclusion, the novel SIRT1 activator MHY2233 reduced lipid accumulation and improved insulin resistance. This finding may contribute toward therapeutic approaches for fatty liver disease and glucose tolerance.
AuthorsMin Jo Kim, Hye Jin An, Dae Hyun Kim, Bonggi Lee, Hye Jin Lee, Sultan Ullah, Su Jeong Kim, Hyoung Oh Jeong, Kyoung Mi Moon, Eun Kyeong Lee, Jungho Yang, Jinia Akter, Pusoon Chun, Hyung Ryong Moon, Hae Young Chung
JournalBioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 28 Issue 4 Pg. 684-688 (02 15 2018) ISSN: 1464-3405 [Electronic] England
PMID29402742 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Benzoxazoles
  • Enzyme Activators
  • Heterocyclic Compounds, 4 or More Rings
  • Hypoglycemic Agents
  • SRT1720
  • Sterol Regulatory Element Binding Proteins
  • Stilbenes
  • Fatty Acid Synthases
  • Sirt1 protein, mouse
  • Sirtuin 1
  • Acetyl-CoA Carboxylase
  • Resveratrol
Topics
  • Acetyl-CoA Carboxylase (genetics)
  • Animals
  • Benzoxazoles (administration & dosage, chemical synthesis, pharmacology)
  • Body Weight
  • Diabetes Mellitus (drug therapy)
  • Enzyme Activators (administration & dosage, chemical synthesis, pharmacology)
  • Fatty Acid Synthases (genetics)
  • Fatty Liver (drug therapy)
  • Gene Expression Regulation (drug effects)
  • Glucose Intolerance (drug therapy)
  • Heterocyclic Compounds, 4 or More Rings (chemistry)
  • Hypoglycemic Agents (administration & dosage, chemical synthesis, pharmacology)
  • Male
  • Metabolic Syndrome (drug therapy)
  • Mice, Inbred C57BL
  • Molecular Docking Simulation
  • Resveratrol
  • Sirtuin 1 (metabolism)
  • Sterol Regulatory Element Binding Proteins (genetics)
  • Stilbenes (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: